vs

Side-by-side financial comparison of AtriCure, Inc. (ATRC) and Jefferson Capital, Inc. (JCAP). Click either name above to swap in a different company.

Jefferson Capital, Inc. is the larger business by last-quarter revenue ($150.8M vs $140.5M, roughly 1.1× AtriCure, Inc.). Jefferson Capital, Inc. produced more free cash flow last quarter ($63.0M vs $18.4M).

AtriCure, Inc. is a global medical device company specializing in the research, development, and manufacturing of innovative surgical tools and therapeutic solutions for treating atrial fibrillation and associated cardiac conditions. Its core customers include hospitals, cardiac surgery centers, and healthcare providers across North America, Europe, and the Asia Pacific region, with products designed to support safer, more effective minimally invasive cardiac procedures.

GE Capital was the financial services division of General Electric. Its various units were sold between 2013 and 2021, including the notable spin-off of the North American consumer finance division as Synchrony Financial. Ultimately, only one division of the company remained, GE Energy Financial Services, which was transferred to GE Vernova when General Electric was broken up.

ATRC vs JCAP — Head-to-Head

Bigger by revenue
JCAP
JCAP
1.1× larger
JCAP
$150.8M
$140.5M
ATRC
More free cash flow
JCAP
JCAP
$44.5M more FCF
JCAP
$63.0M
$18.4M
ATRC

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
ATRC
ATRC
JCAP
JCAP
Revenue
$140.5M
$150.8M
Net Profit
$38.4M
Gross Margin
75.0%
Operating Margin
1.8%
46.4%
Net Margin
25.4%
Revenue YoY
13.1%
Net Profit YoY
EPS (diluted)
$0.04
$0.59

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ATRC
ATRC
JCAP
JCAP
Q4 25
$140.5M
Q3 25
$134.3M
$150.8M
Q2 25
$136.1M
$152.7M
Q1 25
$123.6M
Q4 24
$124.3M
Q3 24
$115.9M
Q2 24
$116.3M
Q1 24
$108.9M
Net Profit
ATRC
ATRC
JCAP
JCAP
Q4 25
Q3 25
$-267.0K
$38.4M
Q2 25
$-6.2M
$47.7M
Q1 25
$-6.7M
Q4 24
Q3 24
$-7.9M
Q2 24
$-8.0M
Q1 24
$-13.3M
Gross Margin
ATRC
ATRC
JCAP
JCAP
Q4 25
75.0%
Q3 25
75.5%
Q2 25
74.5%
Q1 25
74.9%
Q4 24
74.5%
Q3 24
74.9%
Q2 24
74.7%
Q1 24
74.7%
Operating Margin
ATRC
ATRC
JCAP
JCAP
Q4 25
1.8%
Q3 25
0.2%
46.4%
Q2 25
-4.5%
56.7%
Q1 25
-4.8%
Q4 24
-11.7%
Q3 24
-6.4%
Q2 24
-6.2%
Q1 24
-10.0%
Net Margin
ATRC
ATRC
JCAP
JCAP
Q4 25
Q3 25
-0.2%
25.4%
Q2 25
-4.5%
31.2%
Q1 25
-5.5%
Q4 24
Q3 24
-6.8%
Q2 24
-6.9%
Q1 24
-12.2%
EPS (diluted)
ATRC
ATRC
JCAP
JCAP
Q4 25
$0.04
Q3 25
$-0.01
$0.59
Q2 25
$-0.13
$16.76
Q1 25
$-0.14
Q4 24
$-0.33
Q3 24
$-0.17
Q2 24
$-0.17
Q1 24
$-0.28

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ATRC
ATRC
JCAP
JCAP
Cash + ST InvestmentsLiquidity on hand
$167.4M
$42.3M
Total DebtLower is stronger
Stockholders' EquityBook value
$491.9M
$437.4M
Total Assets
$654.2M
$1.8B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ATRC
ATRC
JCAP
JCAP
Q4 25
$167.4M
Q3 25
$147.9M
$42.3M
Q2 25
$117.8M
$51.7M
Q1 25
$99.9M
Q4 24
$122.7M
Q3 24
$130.3M
Q2 24
$114.0M
Q1 24
$106.0M
Total Debt
ATRC
ATRC
JCAP
JCAP
Q4 25
Q3 25
$61.9M
Q2 25
$61.9M
Q1 25
$61.9M
Q4 24
Q3 24
$61.9M
Q2 24
$61.9M
Q1 24
$61.9M
Stockholders' Equity
ATRC
ATRC
JCAP
JCAP
Q4 25
$491.9M
Q3 25
$476.5M
$437.4M
Q2 25
$464.5M
$410.8M
Q1 25
$454.6M
Q4 24
$461.0M
Q3 24
$465.0M
Q2 24
$462.1M
Q1 24
$456.3M
Total Assets
ATRC
ATRC
JCAP
JCAP
Q4 25
$654.2M
Q3 25
$635.4M
$1.8B
Q2 25
$608.8M
$1.8B
Q1 25
$591.6M
Q4 24
$609.3M
Q3 24
$615.1M
Q2 24
$597.3M
Q1 24
$591.6M
Debt / Equity
ATRC
ATRC
JCAP
JCAP
Q4 25
Q3 25
0.13×
Q2 25
0.13×
Q1 25
0.14×
Q4 24
Q3 24
0.13×
Q2 24
0.13×
Q1 24
0.14×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ATRC
ATRC
JCAP
JCAP
Operating Cash FlowLast quarter
$20.0M
$63.1M
Free Cash FlowOCF − Capex
$18.4M
$63.0M
FCF MarginFCF / Revenue
13.1%
41.7%
Capex IntensityCapex / Revenue
1.1%
0.1%
Cash ConversionOCF / Net Profit
1.64×
TTM Free Cash FlowTrailing 4 quarters
$48.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ATRC
ATRC
JCAP
JCAP
Q4 25
$20.0M
Q3 25
$26.7M
$63.1M
Q2 25
$21.6M
$130.6M
Q1 25
$-11.0M
Q4 24
$5.8M
Q3 24
$20.0M
Q2 24
$7.4M
Q1 24
$-21.0M
Free Cash Flow
ATRC
ATRC
JCAP
JCAP
Q4 25
$18.4M
Q3 25
$24.1M
$63.0M
Q2 25
$19.0M
$130.0M
Q1 25
$-13.2M
Q4 24
$3.1M
Q3 24
$16.4M
Q2 24
$5.0M
Q1 24
$-23.8M
FCF Margin
ATRC
ATRC
JCAP
JCAP
Q4 25
13.1%
Q3 25
18.0%
41.7%
Q2 25
13.9%
85.1%
Q1 25
-10.7%
Q4 24
2.5%
Q3 24
14.1%
Q2 24
4.3%
Q1 24
-21.9%
Capex Intensity
ATRC
ATRC
JCAP
JCAP
Q4 25
1.1%
Q3 25
1.9%
0.1%
Q2 25
2.0%
0.4%
Q1 25
1.8%
Q4 24
2.2%
Q3 24
3.1%
Q2 24
2.1%
Q1 24
2.5%
Cash Conversion
ATRC
ATRC
JCAP
JCAP
Q4 25
Q3 25
1.64×
Q2 25
2.74×
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ATRC
ATRC

Appendage Management$45.5M32%
Openheart$38.5M27%
Other$26.2M19%
Pain Management$22.6M16%
Minimally Invasive$7.7M6%

JCAP
JCAP

United States Segment$108.1M72%
Other$35.8M24%
United Kingdom Segment$6.9M5%

Related Comparisons